SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Rydén Göran)
 

Sökning: WFRF:(Rydén Göran) > Tumor co-expression...

  • Berger, Karoline,1991University of Gothenburg,Gothenburg University,Göteborgs universitet,Sahlgrenska Centrum för Cancerforskning (SCCR),Institutionen för biomedicin, avdelningen för laboratoriemedicin,Sahlgrenska Center for Cancer Research (SCCR),Department of Laboratory Medicine,Univ Gothenburg, Sweden (författare)

Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer

  • Artikel/kapitelEngelska2021

Förlag, utgivningsår, omfång ...

  • 2021-02-22
  • Springer Science and Business Media LLC,2021

Nummerbeteckningar

  • LIBRIS-ID:oai:gup.ub.gu.se/302543
  • https://gup.ub.gu.se/publication/302543URI
  • https://doi.org/10.1186/s12885-021-07854-0DOI
  • https://lup.lub.lu.se/record/20785a6b-9c83-4b11-91cc-b85addfcc671URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-174112URI

Kompletterande språkuppgifter

  • Språk:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding Agencies|Assar Gabrielssons Research Foundation; Swedish Cancer Foundation [20 0306 PjF, 2016-438, 2016-486]; Swedish Research CouncilSwedish Research CouncilEuropean Commission [2017-01392, 2016-01530]; Swedish government [716321, 721091]; Swedish county councils, the ALF [716321, 721091]; BioCARE National Strategic Research Program at University of Gothenburg; University of Gothenburg
  • Background The growth factor progranulin has been implicated in numerous biological processes such as wound healing, inflammation and progressive tumorigenesis. Both progranulin and its receptor sortilin are known to be highly expressed in subgroups of breast cancer and have been associated with various clinical properties including tamoxifen resistance. Recent data further suggest that progranulin, via its receptor sortilin, drives breast cancer stem cell propagation in vitro and increases metastasis formation in an in vivo breast cancer xenograft model. In this retrospective biomarker analysis, we aimed to determine whether tumor co-expression of progranulin and sortilin has prognostic and treatment predictive values for breast cancer patients. Methods We explored how co-expression of progranulin and sortilin was associated with established clinical markers by analyzing a tissue microarray including 560 randomized premenopausal breast cancer patients receiving either 2 years of tamoxifen treatment or no adjuvant treatment, with a median follow-up time of 28 years. Breast cancer-specific survival was analyzed using Kaplan-Meier and Cox Proportional Hazards regression models to assess the prognostic and predictive value of progranulin and sortilin in relation to known clinical markers. Results Co-expression of progranulin and sortilin was observed in 20% of the breast cancer samples. In untreated patients, prognostic considerations could be detailed separately from treatment prediction and the high progranulin and sortilin expressing subgroup was significantly associated with breast cancer-specific death in multivariable analyses (HR=2.188, CI: 1.317-3.637, p=0.003) along with tumor size, high tumor grade and lymph node positivity. When comparing the untreated patients with tamoxifen treated patients in the ER alpha positive subgroup, co-expression of progranulin and sortilin was not linked to tamoxifen resistance. Conclusion Data suggest that co-expression of progranulin and its receptor sortilin is a novel prognostic biomarker combination identifying a highly malignant subgroup of breast cancer. Importantly, this subpopulation could potentially be targeted with anti-sortilin based therapies.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Rhost, SaraUniversity of Gothenburg,Gothenburg University,Göteborgs universitet,Sahlgrenska Centrum för Cancerforskning (SCCR),Institutionen för biomedicin, avdelningen för laboratoriemedicin,Sahlgrenska Center for Cancer Research (SCCR),Department of Laboratory Medicine,Univ Gothenburg, Sweden(Swepub:gu)xrhosa (författare)
  • Rafnsdottir, SvanheidurUniversity of Gothenburg,Gothenburg University,Göteborgs universitet,Sahlgrenska Centrum för Cancerforskning (SCCR),Institutionen för biomedicin, avdelningen för laboratoriemedicin,Sahlgrenska Center for Cancer Research (SCCR),Department of Laboratory Medicine,National University Hospital of Iceland,Univ Gothenburg, Sweden; Natl Univ Hosp Iceland, Iceland(Swepub:gu)xrafsv (författare)
  • Hughes, ÉamonUniversity of Gothenburg,Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för laboratoriemedicin,Sahlgrenska Centrum för Cancerforskning (SCCR),Department of Laboratory Medicine,Sahlgrenska Center for Cancer Research (SCCR),Univ Gothenburg, Sweden (författare)
  • Magnusson, Ylva,1967University of Gothenburg,Gothenburg University,Göteborgs universitet,Sahlgrenska Centrum för Cancerforskning (SCCR),Institutionen för biomedicin, avdelningen för laboratoriemedicin,Sahlgrenska Center for Cancer Research (SCCR),Department of Laboratory Medicine,Univ Gothenburg, Sweden(Swepub:gu)xmagyl (författare)
  • Ekholm, MariaLinköpings universitet,Linköping University,Lund University,Lunds universitet,Individuell Bröstcancerbehandling,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Personalized Breast Cancer Treatment,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Jönköping County Council,Institutionen för biomedicinska och kliniska vetenskaper,Medicinska fakulteten,Lund Univ, Sweden; Department of Oncology, Region Jönköping County, Jönköping, Sweden(Swepub:liu)n/a (författare)
  • Stål, OlleLinköpings universitet,Linköping University,Jönköping County Council,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US,3 Department of Oncology, Region Jönköping County, Jönköping, Sweden(Swepub:liu)ollst87 (författare)
  • Rydén, LisaLund University,Lunds universitet,The Liquid Biopsy och Tumörprogression i Bröstcancer,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,The Liquid Biopsy and Tumor Progression in Breast Cancer,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Lund Univ, Sweden(Swepub:lu)pat-lry (författare)
  • Landberg, Göran,1963University of Gothenburg,Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för laboratoriemedicin,Sahlgrenska Centrum för Cancerforskning (SCCR),Department of Laboratory Medicine,Sahlgrenska Center for Cancer Research (SCCR),Univ Gothenburg, Sweden(Swepub:lu)pat-gla (författare)
  • Göteborgs universitetSahlgrenska Centrum för Cancerforskning (SCCR) (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:BMC Cancer: Springer Science and Business Media LLC21:11471-2407

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy